Trastuzumab deruxtecan (solution)

Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC) . Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) . Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer[1][2].

Product Specifications

CAS Number

[1826843-81-5]

Product Name Alternative

DS-8201 (solution) ; DS-8201a (solution)

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; EGFR

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/trastuzumab-deruxtecan-solution.html

Purity

99.64

Solubility

H2O

Smiles

[Trastuzumabderuxtecan]

Molecular Weight

153000 (average)

References & Citations

[1]Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518.|[2]Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107 (7) :1039-46.|[3]Iwata TN, et, al. [Fam-] trastuzumab deruxtecan (DS-8201a) -induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS One. 2019 Oct 1;14 (10) :e0222280.|[4]Kumagai K, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020 Dec;111 (12) :4636-4645.